Brian Stanley (Laois, Independent)
Link to this: Individually | In context

1551. To ask the Minister for Health further to Parliamentary Question No. 787 of 20 May 2025, around the reimbursement list scheme, the answer states that liraglutide (saxenda) is the only product currently approved under community drug schemes GMS/DPS for weight management, to clarify the criteria for use; if a person needs to be in diagnosis of prediabetes or can other factors such as high cardiovascular disease, hypertension or sleep apnoea qualify a patient for this drug therapy; and if she will make a statement on the matter. [30151/25]

Jennifer Carroll MacNeill (Dún Laoghaire, Fine Gael)
Link to this: Individually | In context

Under the Health (Pricing and Supply of Medical Goods) Act 2013, the HSE has statutory responsibility for decisions on the pricing and reimbursement of medicines and medical devices including reimbursement for specific indications; therefore, the matter has been referred to the HSE for attention and direct reply to the Deputy.